(AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 ...

As the nation's largest organization serving the critical needs of blood cancer patients, we are alarmed by recent actions ...

Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

Unrelated cord blood transplant demonstrated efficacy in patients with blood cancer after microcystic adnexal carcinoma.

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of ...

Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

(AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year ...

Study Progresses to Fourth Higher 90 mg/m2Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast ...

In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...

She'll pretend to be a "pet doctor" and take care of them. When she got to pick her wish, she wanted to have her own vet ...

If Maggie O'Neil can't find a match among family members, she'll have to turn to a global nonprofit that connects volunteer ...